Protocols

Ablynx grabs a €15M milestones payment from Merck KGaA; EyeGate surges on Valeant payout

→ Belgium’s Ablynx has teed up one of its Nanobodies for osteoarthritis for Merck KGaA. The German company accepted it and will now take it into the clinic, triggering a €15 million milestone payment.

→ JDRF says it will support ViaCyte’s work on a Type 1 diabetes program.

→ Shares of EyeGate Pharmaceuticals $EYEG jumped on the news that it has grabbed a development milestone from Valeant for its pact covering the EyeGate II Delivery System and EGP-437 combination product for post-operative ocular inflammation and pain in ocular surgery patients.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017